124. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Clinical trials / Disease details


臨床試験数 : 12 薬物数 : 14 - (DrugBank : 5) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 11

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs051220072
09/08/202209/08/2022Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and LeukoencephalopathyEffect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy - LOMCAD Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
CADASIL;D046589
Lomerizine hydrochloride (MIGSYS tablets 5 mg, 1 tablet twice daily) will be administered continuously for 24 months as the study drug.Mizuno ToshikiNULLRecruiting>= 20age old<= 70age oldBoth20N/AJapan
2NCT04334408
(ClinicalTrials.gov)
December 20212/4/2020Safety and Efficacy of Fremanezumab for Migraine in Adult CADASILA Phase II Double-Blinded Placebo Controlled Individual Subject Stepped Wedge Clinical Trial Evaluating the Safety and Efficacy of Fremanezumab for Migraine in Adult CADASILCadasil;MigraineDrug: Fremanezumab;Drug: PlaceboMayo ClinicNULLNot yet recruiting18 Years70 YearsAll5Phase 2United States
3NCT04658823
(ClinicalTrials.gov)
December 21, 202029/11/2020Efficacy and Safety of Tocotrienols in CADASILA Randomized Placebo-controlled Double-blind Pilot / Phase II Study to Assess the Efficacy and Safety of HOV-12020 in Patients With Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)CadasilDrug: HOV-12020 (Palm tocotrienols complex);Drug: PlaceboHovid BerhadNULLActive, not recruiting45 Years75 YearsAll50Phase 2France
4NCT01361763
(ClinicalTrials.gov)
June 201116/5/2011Safety Study of Dabigatran in CADASILPhase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASILCADASILDrug: Dabigatran;Drug: AntiplateletsS. Andrea HospitalNULLRecruiting18 YearsN/ABoth50Phase 2Italy
5EUCTR2007-004370-55-IT
(EUCTR)
14/12/200711/12/2007Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4 CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulthood and leading in some to severe motor disability with pseudobulbar palsy and dementia of the subcortical type
MedDRA version: 9.1;Level: HLGT;Classification code 10008804;Term: Chromosomal abnormalities and abnormal gene carriers
Product Name: Phenoptin
Product Code: 6R-BH4
INN or Proposed INN: sapropterin
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)NULLNot RecruitingFemale: yes
Male: yes
Italy
6EUCTR2004-001162-40-IT
(EUCTR)
05/04/200521/09/2005An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment. Donezepil HCl for treatment of patients with CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy) who have cognitive impairment.
MedDRA version: 6.1;Level: PT;Classification code 10009843
Trade Name: ARICEPT 5*28 CPR 5 MG
Product Name: NA
Product Code: NA
INN or Proposed INN: Donepezil
EISAI LTD UKNULLNot RecruitingFemale: yes
Male: yes
Finland;United Kingdom;Germany;Spain;Italy;Sweden
7EUCTR2004-001162-40-SE
(EUCTR)
01/04/200503/02/2005An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride
Eisai LtdNULLNot RecruitingFemale: yes
Male: yes
150Finland;United Kingdom;Germany;Spain;Italy;Sweden
8EUCTR2004-001162-40-ES
(EUCTR)
29/03/200520/01/2006An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride
Eisai LtdNULLNot Recruiting Female: yes
Male: yes
150 Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4):Finland;Spain;Germany;Italy;United Kingdom;Sweden
9EUCTR2004-001162-40-FI
(EUCTR)
08/03/200528/12/2004An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride
Eisai LtdNULLNot RecruitingFemale: yes
Male: yes
150Phase 2Finland;Spain;Germany;Italy;United Kingdom;Sweden
10EUCTR2004-001162-40-GB
(EUCTR)
24/02/200523/02/2005An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride
Eisai LtdNULLNot Recruiting Female: yes
Male: yes
150 Human pharmacology (Phase 1): Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): Therapeutic use (Phase 4):Finland;Spain;Germany;Italy;United Kingdom;Sweden
11NCT00103948
(ClinicalTrials.gov)
February 200517/2/2005The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive ImpairmentAn 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive ImpairmentCognitive ImpairmentDrug: AriceptEisai LimitedNULLCompleted25 Years70 YearsBoth165Phase 2United States;Australia;Spain;Canada;Finland;France;Germany;Italy;Sweden;Switzerland;United Kingdom
12EUCTR2004-001162-40-DE
(EUCTR)
25/01/2005An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678
Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride
Eisai LtdNULLNot RecruitingFemale: yes
Male: yes
150Finland;Spain;Germany;Italy;United Kingdom;Sweden